George Coukos
Auto-generated profile, based on publicly available information

George Coukos

Ludwig Institute for Cancer Research, Department of Oncology, University of Lausanne and Lausanne University Hospital (CHUV), Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2004 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TCTyler J Curiel
Tyler J Curiel
GCGeorge Coukos
George Coukos
LZLinhua Zou
Linhua Zou
XAXavier Alvarez
Xavier Alvarez
PCPui Cheng
Pui Cheng
WZWeiping Zou
Weiping Zou

21 December 2011 in Nature
Verified
Journal Article
Closed access
PDF file
IMIra Mellman
Ira Mellman
GCGeorge Coukos
George Coukos
GDGlenn Dranoff
Glenn Dranoff

16 January 2003 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LZLin Zhang
Lin Zhang
JCJose R Conejo-Garcia
Jose R Conejo-Garcia
DKDionyssios Katsaros
Dionyssios Katsaros
PGPhyllis A. Gimotty
Phyllis A. Gimotty
MMMarco Massobrio
Marco Massobrio
GCGeorge Coukos
George Coukos
Although tumor-infiltrating T cells have been documented in ovarian carcinoma, a clear association with clinical outcome has not been established. We performed immunohistochemical analysis of 186 frozen specimens from advanced-stage ovarian carcinomas to assess the distribution of tumor-infiltrating T cells and conducted outcome analyses. Molecular analyses were performed in some tumors by real-time polymerase chain reaction. CD3+ tumor-infiltrating T cells were detected within tumor-cell islets (intratumoral T cells) in 102 of the 186 tumors (54.8 percent); they were undetectable in 72 tumors (38.7 percent); the remaining 12 tumors (6.5 percent) could not be evaluated. There were significant differences in the distributions of progression-free survival and overall survival according to the presence or absence of intratumoral T cells (P<0.001 for both comparisons). The five-year overall survival rate was 38.0 percent among patients whose tumors contained T cells and 4.5 percent among patients whose tumors contained no T cells in islets. Significant differences in the distributions of progression-free survival and overall survival according to the presence or absence of intratumoral T cells (P<0.001 for both comparisons) were also seen among 74 patients with a complete clinical response after debulking and platinum-based chemotherapy: the five-year overall survival rate was 73.9 percent among patients whose tumors contained T cells and 11.9 percent among patients whose tumors contained no T cells in islets. The presence of intratumoral T cells independently correlated with delayed recurrence or delayed death in multivariate analysis and was associated with increased expression of interferon-γ, interleukin-2, and lymphocyte-attracting chemokines within the tumor. The absence of intratumoral T cells was associated with increased levels of vascular endothelial growth factor. The presence of intratumoral T cells correlates with improved clinical outcome in advanced ovarian carcinoma.

13 July 2011 in Nature
Verified
Journal Article
Closed access
AFAndrea Facciabene
Andrea Facciabene
XPXiaohui Peng
Xiaohui Peng
IHIan Hagemann
Ian Hagemann
KBKlara Balint
Klara Balint
ABAndrea Barchetti
Andrea Barchetti
GCGeorge Coukos
George Coukos

23 October 2015 in Nature Reviews Cancer
Verified
Journal Article
Open access
PDF file
DBDavid D. Bowtell
David D. Bowtell
SBSteffen Böhm
Steffen Böhm
AAAhmed A. Ahmed
Ahmed A. Ahmed
PAPaul-Joseph Aspuria
Paul-Joseph Aspuria
Robert BastRobert Bast
Robert Bast
FBFrances R. Balkwill
Frances R. Balkwill
This Opinion article outlines a set of research priorities, based on discussions held at the 2015 Helene Harris Memorial Trust Ovarian Cancer Action meeting, that the authors believe will reduce incidence and improve outcomes for women with high-grade serous ovarian cancer. High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.

23 September 2011 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
SVSebastian Vaughan
Sebastian Vaughan
JCJermaine I. Coward
Jermaine I. Coward
Robert BastRobert Bast
Robert Bast
ABAndy Berchuck
Andy Berchuck
JBJonathan S. Berek
Jonathan S. Berek
FBFrances R. Balkwill
Frances R. Balkwill